Literature DB >> 15307433

Artesunate plus sulfadoxine-pyrimethamine for uncomplicated malaria in Kenyan children: a randomized, double-blind, placebo-controlled trial.

Charles O Obonyo1, Francis Ochieng, Walter R J Taylor, Samuel A Ochola, Kefas Mugitu, Piero Olliaro, Feiko ter Kuile, Aggrey J Oloo.   

Abstract

Plasmodium falciparum has developed resistance to almost all routinely used antimalarial drugs. Sulfadoxine-pyrimethamine (SP) has replaced chloroquine as first-line treatment of uncomplicated malaria infection in Kenya but resistance to SP is already reported. The addition of artemisinin derivatives to SP may delay the development of drug resistance, improve cure rates, and reduce transmission. The efficacy and safety of artesunate plus SP in the treatment of uncomplicated P. falciparum malaria was evaluated in a randomized trial of 600 children at Siaya District Hospital, western Kenya between October 1999 and March 2000. Children aged < 5 years were randomly assigned to receive SP alone (1.25 mg/kg based on pyrimethamine), or in combination with artesunate (4 mg/kg/d) for either 1 or 3 d. Parasitological failure by days 14 and 28 (polymerase chain reaction [PCR]-corrected for new infections) were the primary endpoints. Treatment failure rates by day 14 were 25.5% in the SP alone group, 16.2% (risk difference [delta]-9.3%, 95% CI -17.3 to -1.2%, P= 0.027) in the 1-dose artesunate group, and 9.4% (delta-16.2%, 95% CI -23.6 to -8.7%, P< 0.001) in the 3-dose artesunate group. Corresponding rates by day 28 were 46.0% in the SP alone group, 38.2% (delta-7.8%, 95% CI -17.7 to 2.1%, P= 0.16) in the 1-dose artesunate group, and 26.0% (delta-20.0%, 95% CI -29.4 to -10.6%, P < 0.001) in the 3-dose artesunate group. The artesunate and SP combination was well tolerated. There were no serious drug-related adverse events. Parasite clearance and gametocyte carriage were reduced significantly in both combination groups compared with SP alone. Three days of artesunate were required to reduce significantly the risk of treatment failure by day 28. However, the high background rate of parasitological failure with SP may make this combination unsuitable for widespread use in Kenya.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15307433     DOI: 10.1016/s0035-9203(03)80038-x

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  15 in total

1.  A reversal in reductions of child mortality in western Kenya, 2003-2009.

Authors:  Mary J Hamel; Kubaje Adazu; David Obor; Maquins Sewe; John Vulule; John M Williamson; Laurence Slutsker; Daniel R Feikin; Kayla F Laserson
Journal:  Am J Trop Med Hyg       Date:  2011-10       Impact factor: 2.345

2.  Lack of impact of artesunate on the disposition kinetics of sulfadoxine/pyrimethamine when the two drugs are concomitantly administered.

Authors:  O M S Minzi; A Gupta; A F Haule; G A B Kagashe; A Y Massele; L L Gustafsson
Journal:  Eur J Clin Pharmacol       Date:  2007-02-27       Impact factor: 2.953

3.  Intermittent preventive treatment in infants for the prevention of malaria in rural Western kenya: a randomized, double-blind placebo-controlled trial.

Authors:  Frank O Odhiambo; Mary J Hamel; John Williamson; Kim Lindblade; Feiko O ter Kuile; Elizabeth Peterson; Peter Otieno; Simon Kariuki; John Vulule; Laurence Slutsker; Robert D Newman
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240

4.  Changing malaria intervention coverage, transmission and hospitalization in Kenya.

Authors:  Emelda A Okiro; Victor A Alegana; Abdisalan M Noor; Robert W Snow
Journal:  Malar J       Date:  2010-10-15       Impact factor: 2.979

5.  Gaps between Knowledge and Malaria Treatment Practices after Intensive Anti-Malaria Campaigns in Western Kenya: 2004-2016.

Authors:  Guofa Zhou; Elizabeth Hemming-Schroeder; Maxwell Gesuge; Yaw A Afrane; Ming-Chieh Lee; Harrysone E Atieli; Andrew K Githeko; Guiyun Yan
Journal:  Am J Trop Med Hyg       Date:  2020-06       Impact factor: 2.345

6.  Efficacy and Tolerability of Malartin and Sulphadoxine-Pyrimethamine Combination against Uncomplicated Falciparum Malaria in Dibanda, Southwest Cameroon.

Authors:  Helen Kuokuo Kimbi; Mesame Ntoko; Nelson N Ntonifor; Emmaculate Lum; Anna L Njunda; Peter Nde Fon
Journal:  J Trop Med       Date:  2012-02-29

7.  Artesunate plus sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in Sudan.

Authors:  Sakina B Elamin; Elfatih M Malik; Tarig Abdelgadir; Ammar H Khamiss; Mamoun M Mohammed; Elderderi S Ahmed; Ishag Adam
Journal:  Malar J       Date:  2005-09-14       Impact factor: 2.979

8.  Efficacy of Pyrimethamine/Sulfadoxine versus Chloroquine for the Treatment of Uncomplicated Falciparum Malaria in Children Aged Under 5 Years.

Authors:  W Zheng; H Jiang; Z Xiong; Z Jiang; H Chen
Journal:  Iran J Parasitol       Date:  2013-01       Impact factor: 1.012

9.  A randomized, open-label, comparative efficacy trial of artemether-lumefantrine suspension versus artemether-lumefantrine tablets for treatment of uncomplicated Plasmodium falciparum malaria in children in western Kenya.

Authors:  Elizabeth A Juma; Charles O Obonyo; Willis S Akhwale; Bernhards R Ogutu
Journal:  Malar J       Date:  2008-12-22       Impact factor: 2.979

10.  The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya.

Authors:  Abdinasir A Amin; Dejan Zurovac; Beth B Kangwana; Joanne Greenfield; Dorothy N Otieno; Willis S Akhwale; Robert W Snow
Journal:  Malar J       Date:  2007-05-29       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.